A&R Logistics Enters Into Collaboration Agreement With Union Pacific

A&R Logistics announced today that it has entered into a collaboration agreement with Union Pacific to co-develop an export supply chain solution for the U.S. plastic resin industry.

This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.

A&R Logistics ("A&R") announced today that it has entered into a collaboration agreement with Union Pacific ("UP") to co-develop an export supply chain solution for the U.S. plastic resin industry. The project will be aimed at
establishing a transportation and plastics packaging facility near UP's Dallas Intermodal Terminal to handle the anticipated significant increase in export plastic resins.

Commenting on the agreement, Mark R. Holden, CEO, stated "approximately $50 billion is expected to be invested in the U.S. over the next 10 years by the Plastics Industry to expand production. Thanks to growth in domestic shale gas production, the U.S. plastics industry is benefitting from feedstocks derived largely from natural gas. As a result, the export of plastic resins is expected to surge over the next decade. Net
exports are expected to more than triple, growing from $6.5 billion in 2014 to $21.5 billion by 2030."

Holden further commented "A&R looks to develop a state-of-the art packaging facility and transportation related product to provide what we believe will be the most flexible and efficient supply chain for the export of plastic resins in the U.S."

Researched List: Blister Machines for Life Sciences
Need a blister machine for life sciences packaging? Our curated list features companies serving pharmaceutical, medical device, nutraceutical, and cosmetic industries. Download to access company names, locations, machine specifications, descriptions, and more.
Download Now
Researched List: Blister Machines for Life Sciences
FDA warning letters surge - is your team prepared?
New guide reveals expert strategies to prevent regulatory issues and respond effectively to FDA enforcement actions in pharmaceutical and medical device manufacturing.
Read More
FDA warning letters surge - is your team prepared?